BridgeBio Eyes Three Product Launches as Attruby Shows Kidney Protection Data
The biotech reported 23% growth for its ATTR treatment while advancing three late-stage programs toward regulatory approval, with the first decision expected in November.
Portfolio Expansion Accelerates
BridgeBio Pharma outlined what CEO Neil Kumar called "t=0 in BridgeBio's next chapter" during its second-quarter 2026 earnings call, pointing to commercial momentum for its approved drug Attruby and three new drug applications now under FDA review (earnings call, 2026-08-10).
The company's commercial-stage cardiac therapy Attruby grew 23% in the quarter, making it "the fastest-growing brand in the space," Kumar said. The overall ATTR cardiomyopathy market expanded 19% in the quarter, representing 51% year-over-year growth and "substantially outstripping the market growth observed in the last 3 quarters" (earnings call, 2026-08-10).
Kidney Protection Data Emerges
BridgeBio published new data in July showing acoramidis (Attruby) delivers "the first ever early and sustained direct kidney protective effects in ATTR cardiomyopathy," including chronic eGFR slope improvement and urinary albumin reduction (earnings call, 2026-08-10). The company characterized this as a "hemodynamically mediated effect" not observed with competing ATTR treatments.
In patient subgroups with acute eGFR dips at or above the median, acoramidis showed a hazard ratio of 0.42 for all-cause mortality or cardiovascular hospitalization (p=0.006) and 0.3 for cardiovascular hospitalization alone (p=0.002) compared to placebo (earnings call, 2026-08-10).
The company also referenced independent real-world evidence showing a "37% reduction in composite cardiovascular events and a 34% reduction in hospitalizations at 6 months relative to tafamidis" in a propensity-matched analysis presented at SCAI (earnings call, 2026-08-10). BridgeBio's own analysis demonstrated a "34% reduction in diuretic intensification, heart failure hospitalization and mortality" with statistical significance (earnings call, 2026-08-10).
Three NDAs Under Review
The FDA accepted BridgeBio's NDA for BBP-418 in limb-girdle muscular dystrophy type 2I (LGMD2I) with priority review on May 27, setting a PDUFA date of November 27, 2026, with no advisory committee planned (earnings call, 2026-08-10). If approved, it would become "the first approved therapy for LGMD2I," a condition affecting roughly 1,000 U.S. patients (earnings call, 2026-08-10).
Two additional NDAs for ADH1 and achondroplasia have been submitted, with LGMD2I and ADH1 receiving priority review designations. Kumar noted the company's commercial readiness efforts are "on track, even ahead of what we were able to do with ATTR cardiomyopathy" (earnings call, 2026-08-10).
Pipeline and Financial Position
BridgeBio highlighted its chronic hypoparathyroid Phase III trial, which has commenced with readout expected within 18 months, positioned as "the only oral in the space" (earnings call, 2026-08-10). The company also plans novel trials for infigratinib in Turner syndrome and hypochondroplasia, plus studies in an undisclosed orphan kidney disease for acoramidis.
Kumar characterized the portfolio as representing "well over $10 billion in risk-adjusted revenue with $8 billion of that being post Phase III today" (earnings call, 2026-08-10). The company completed a $1 billion preferred equity financing on July 1 to support the three upcoming launches.
MarginX data shows recent insider activity including option exercises by executives Cook and Ellis of 17,167 shares each, and a 2,000-share sale by Apuli.
This article was generated by MarginX from the earnings call on 2026-08-10. It is not investment advice.